Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hypophosphatemia

• Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
• Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia
• Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH
• Anti-FGF23 (Burosumab) in Adult Patients With XLH
• Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU
• Burosumab in Children and Adolescents With X-linked Hypophosphatemia
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
• Examining the Effect of Burosumab on Muscle Function
• Burosumab for CSHS
• Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
• Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
• The Impact of Phosphate Metabolism on Healthy Aging
• Calcitriol Monotherapy for X-Linked Hypophosphatemia
• A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
• Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
• Study of the Safety, Pharmacodynamics and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
• Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
• Study of KRN23, a Recombinant Fully Human Monoclonal Antibody Against FGF23, in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
• Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
• Investigating a New Way of Giving Medicine to Newborn and Preterm Babies
• Calcitonin for Treating X-linked Hypophosphatemia
• An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
• A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
• Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
• Hypophosphatemic Rickets in Norway
• Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
• Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
• A Study of KRN23 in X-linked Hypophosphatemia
• FGF-23 Suppressibility by Calcitonin
• Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
• Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets